The renal nerves contribute to hypertension through effects in the kidney that enhance sodium retention and renin secretion, and by effects in the central nervous system that increase systemic sympathetic activity. Therefore, targeting the renal nerves provides a logical basis for treating hypertension. Several trials of renal denervation-achieved by applying radiofrequency energy through catheters placed in the renal arteries-have been completed. Clinical results have been incon-sistent, however, partly because of factors related to the ablation technique and partly because these studies have been performed in patients with the inadequately defined clinical condition of ''treatmentresistant hyper-tension.'' This statement now explains our conclusion that future studies of renal denervation should be guided by the established randomized, controlled clinical trial designs used for studying antihypertensive drugs and other treatments for hypertension.
BackgroundEven before the treatment of hypertension became routine, it was understood that high levels of blood pressure (BP) were associated with premature death, stroke, cardiovascular events, and renal failure. One of the early and effective interventions for severe or symptomatic hypertension was the use of surgical sympathectomy. 1 Although this technique was useful in reducing BP and improving survival, major side effects such as disabling postural hypotension and sexual dysfunction were important limiting factors. Later, many of the early drugs developed for treating hypertension were also based on interrupting the sym-pathetic nervous system, but, again, their side effects-although not as severe as those associated with surgical intervention-made these drugs difficult to use.